TLX
Telix Pharmaceuticals Limited
TLX
Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited (TLX) Q2 2026 Earnings Call Transcript
Telix Pharmaceuticals NASDAQ: TLX reported first-half 2026 revenue of $477 million, up 22% from the prior-year period, as demand for its precision medicine imaging products continued to grow. The comp
Telix is evolving into a vertically integrated radiopharmaceutical platform, leveraging diagnostics, therapeutics, isotope generation, and distribution for a durable competitive edge. TLX's Illuccix a
MELBOURNE, Australia and INDIANAPOLIS, July 16, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and St Vincent's Hospital today announced that the first patient